System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Pierre Duquette is an expert in Neurology at Centre Hospitalier de l’Université de Montréal (Canada). As of August 2026, ScienceLeadR ranks Pierre Duquette in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. Pierre Duquette has authored 288 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 1 of them ongoing. SLR score: 781 (community average: 125). How the SLR is computed.

LeadR Profile

Pierre Duquette Centre Hospitalier de l’Université de Montréal Canada
781 ScienceLeadR Reputation 781

Unlock

Register Login
Network Map

Neurology

Subspecialties: Psychiatry - Psychology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1975 - 2026
Source: PubMed

Centre Hospitalier de l’Université de Montréal

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 288

Citations

Citations: 14 961 1st author: 21 Last author: 27 Unique author: 5

Main journals

Mult Scler 44
Neurology 37
J Neurol Neurosurg Psychiatry 14
Mult Scler Relat Disord 11
Can J Neurol Sci 10

Best Journals

N Engl J Med 3
JAMA 1
Lancet Neurol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.
PMID 42543909 — sclerosis, multiple sclerosis, neoplasms, drug therapy, diagnosis, therapeutics, chemotherapy		Mult Scler20260
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.
PMID 42496160 — sclerosis, multiple sclerosis, incidence, therapeutics, wounds and injuries, neurology, multiple sclerosis, relapsing-remitting		Brain20260
Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and pain.
PMID 42145652 — depression, sclerosis, multiple sclerosis, pain, fatigue, cognition		Mult Scler J Exp Transl Clin20260
Multiple sclerosis disability progression and predictors: A retrospective cohort study over five decades from a Canadian registry.
PMID 41781303 — registries, sclerosis, multiple sclerosis, cohort studies, sex, therapeutics, neurology, age of onset		Rev Neurol (Paris)20260
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.
PMID 41466847 — registries, sclerosis, multiple sclerosis, treatment switching, therapeutics		Ther Adv Neurol Disord20250

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

N/A 4
Phase 3 4
Phase 2 1
Phase 4 1

By status:

Completed 6
Unknown 2
Recruiting 1
Terminated 1

By type:

Interventional 9
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Cannabis as a Complementary Treatment in Multiple Sclerosis
NCT05092191 — dronabinol, sclerosis, multiple sclerosis, safety, blood, informed consent, signs and symptoms, research, therapeutics, neurologists, cannabinoids		Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS